bio

Biointron is proud to share that we have received the 2024 Scientist.com Supplier Performance Recognition Award, for our dedication to providing high-quality drug discovery research services on this industry-renowned R&D sourcing platform.

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

Biointron delivers results in just 2 weeks. Our ISO-certified platforms accelerate antibody services, ensuring high-quality, fast, and reliable outcomes.

Biointron is excited to announce our participation in BioPlus-Interphex Korea 2025, taking place October 15-17, 2025, in Seoul, South Korea. This premier event brings together leaders in biotechnology, pharmaceuticals, and healthcare to showcase innovations, discuss industry trends, and foster collaboration across the life sciences sector.

According to Research and Markets, the global market for Fc and glycoengineered antibodies is projected to be worth US$38.8 billion in 2024. Over the next decade, the growth in opportunities for drug developers is expected to be driven by an increasing patient population and rising demand for these

Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected mosquitoes. Of the five species of Plasmodium that cause malaria, Plasmodium falciparum is the deadliest, responsible for the majority of cases and deaths, particularly in Africa, where young children are

Biointron is excited to announce our participation in BIO Asia-Taiwan 2025, taking place July 24-27, 2025, in Taipei, Taiwan. As one of Asia’s largest biotech gatherings, this event unites global industry leaders, researchers, and innovators to discuss cutting-edge developments and opportunities in the life sciences.

Biointron is thrilled to announce our participation in the BIO International Convention 2025, set for June 16-19, 2025, in Boston, MA. As the world’s largest gathering of biotechnology and life sciences professionals, this event offers unparalleled opportunities to connect with global innovators, share cutting-edge research, and explore transformative solutions in biotech and healthcare.

Biointron is thrilled to announce our participation in BIO KOREA 2025, scheduled for May 7-9, 2025, in Seoul, South Korea. Biointron is proud to join this dynamic forum and contribute to the advancement of biopharmaceutical science and innovation.

Biointron is excited to announce our participation in Swiss Biotech Day 2025, taking place on May 5-6, 2025, in Basel, Switzerland.

Biointron is delighted to announce our participation in the NextGen Biomed Europe 2025 Conference, happening on March 12-14, 2025, in London, UK.

Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-

Top biotechs choose Biointron to accelerate antibody production. Our CRO expertise ensures speed, reliability, and global delivery of antibody solutions.

The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which

Partner with Biointron for antibody discovery. Our CRO expertise delivers custom antibodies and scalable solutions that accelerate therapeutic development.